Behavioral Science at Work
XIIDRA INSIDER DRIVES 30%
HIGHER PRESCRIPTION FILL RATE

Xiidra® and Response launch data-driven CRM

to educate and activate dry eye patients.

Dry eye disease (DED) impacts over 38 million people in the US.

Yet, it continues to be widely misunderstood and underdiagnosed. Chronic dry eye, caused by aging, environmental factors, and increased screen time can lead to long-term vision issues and persistent discomfort if left untreated. Unlike OTC drops that merely put a Band-Aid on symptoms, Xiidra® (lifitegrast ophthalmic solution 5%) is the only nonsteroid anti-inflammatory prescription drop that targets the root cause of inflammation.

key strategies

Create a strategic data-capture framework to understand individual sufferers.
Educate sufferers and position Xiidra as the #1 choice for dry eye inflammation.
Understand and overcome barriers to treatment initiation.
Bolster beliefs and navigate concerns to ensure adherence and long-term patient success

Response conducted behavioral science–based primary research to understand the undiagnosed patient mindset and identify barriers to treatment adoption and persistence. Insights into treatment frustrations, medication beliefs, and concerns shaped a personalized communication strategy aligned to patients’ psychological readiness.

Stage-specific messaging addressed doubts, reduced friction, and motivated action across the patient journey, reinforced by social proof and testimonials from everyday users and celebrity patient Julie Bowen.

This approach translated insight into action through personalized content and email journeys, educating dry eye sufferers, increasing prescriptions, and significantly improving treatment persistence. 

Key results

Xiidra insider drove 30% higher prescription fill rates compared to non-members.
Xiidra insider members were 2X more likely to continue successfully using Xiidra at month 7 compared to non-members.
55% engaged with personalized content designed to convert belief into action (4X higher engagement than benchmark).
Xiidra insider members accounted for approx. 1/3 of new patients making copay claims, indicating the platform was a significant contributor to new Xiidra prescriptions.
65% of new members enrolled in the program were chronic dry eye sufferers not currently using a prescription treatment.
Together, Xiidra and Response set a clearer vision for dry eye care, delivering more impactful patient journeys and improved health outcomes.

Turn your challenge into 
our next success case.